Value
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 6.0 |
| P/S | 10.0 |
| EV/EBITDA | 6.8 |
| Fwd P/E | 9.4 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 9.3x
- ▸PEG: 0.33
- ▸Attractively valued
ARDT · Why this verdict
Why Ardent Health (ARDT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroRISK_OFF
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Ardent beat estimates in all 4 of the last quarters with an average surprise of 53%, including a 44% beat in August. Earnings | The November 4 report extends the streak to 5 consecutive beats. | ↑Improving |
| CounterEstimates are small per-share figures, so large percentage surprises may reflect conservative analyst numbers, and a streak this strong sets a high bar that is easy to miss. | ||
The stock is attractively valued at a forward P/E of 9.6x and a PEG of 0.28, backed by 266% FCF/net income and a Piotroski F-Score of 7/9. Valuation breakdown | Forward earnings hold and FCF stays above net income. | →Stable |
| CounterNet margin is thin (0.6 component) and there is no moat, so the high cash ratio reflects low net income more than strong cash generation. | ||
Price is 8.4% above the analyst target, so analysts see no upside and reward-to-risk is negative at -0.6. Warnings | Analyst targets are raised above the current price after strong results. | ↑Improving |
| CounterTargets typically lag a beat-driven rerating, so a good report could lift targets above the price. | ||
Revenue is declining 1% year over year at a $1.7B market cap, with leverage penalty from debt-to-equity of 1.3. Growth breakdown | Revenue growth turns positive within 12 months. | →Stable |
| CounterEarnings growth scores a perfect 10 despite flat revenue, indicating margin gains that can continue without sales growth. | ||
Earnings in 3 days, 12% short interest, a put/call ratio of 3.50 and 105% implied volatility signal binary event risk. Key risks | Short interest falls below 8% and implied volatility falls after the report. | ↑Improving |
| CounterHigh short interest combined with a likely beat could produce a squeeze that benefits holders. | ||
Ardent beat estimates in all 4 of the last quarters with an average surprise of 53%, including a 44% beat in August.
↑ImprovingEarnings
- Expectation
- The November 4 report extends the streak to 5 consecutive beats.
CounterEstimates are small per-share figures, so large percentage surprises may reflect conservative analyst numbers, and a streak this strong sets a high bar that is easy to miss.
The stock is attractively valued at a forward P/E of 9.6x and a PEG of 0.28, backed by 266% FCF/net income and a Piotroski F-Score of 7/9.
→StableValuation breakdown
- Expectation
- Forward earnings hold and FCF stays above net income.
CounterNet margin is thin (0.6 component) and there is no moat, so the high cash ratio reflects low net income more than strong cash generation.
Price is 8.4% above the analyst target, so analysts see no upside and reward-to-risk is negative at -0.6.
↑ImprovingWarnings
- Expectation
- Analyst targets are raised above the current price after strong results.
CounterTargets typically lag a beat-driven rerating, so a good report could lift targets above the price.
Revenue is declining 1% year over year at a $1.7B market cap, with leverage penalty from debt-to-equity of 1.3.
→StableGrowth breakdown
- Expectation
- Revenue growth turns positive within 12 months.
CounterEarnings growth scores a perfect 10 despite flat revenue, indicating margin gains that can continue without sales growth.
Earnings in 3 days, 12% short interest, a put/call ratio of 3.50 and 105% implied volatility signal binary event risk.
↑ImprovingKey risks
- Expectation
- Short interest falls below 8% and implied volatility falls after the report.
CounterHigh short interest combined with a likely beat could produce a squeeze that benefits holders.
Per-dimension breakdown
Quality
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 3.3 |
| ROA | 2.1 |
| Gross margin | 7.7 |
| Op margin | 1.4 |
| Net margin | 0.6 |
| Current ratio | 7.3 |
| FCF quality | 10.0 |
| Moat | 4.6 |
| Piotroski F | 7.8 |
- ▸Excellent cash conversion: 266% FCF/NI
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 7/9
Growth
6.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 2.1 |
| EPS growth | 10.0 |
- ▸Declining revenue: -1%
Momentum
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 6.7 |
| OBV | 5.2 |
| MA position | 9.0 |
| Volume | 10.0 |
| vol acceleration | 8.2 |
- ▸Above 200-day MA
- ▸Volume surge (2.1x avg) on up move
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.5 |
| Analyst rating | 7.1 |
| Price target | 4.6 |
- ▸LLM news sentiment: +0.50 (n=2)
Insider
6.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.9 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.0 |
| quality rank | 3.2 |
| growth rank | 0.9 |
Technical
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 1.0 |
| 52w position | 6.8 |
| gap | 4.0 |
Risk (lower is worse)
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.9 |
| days to cover | 2.6 |
| volatility | 3.1 |
| put call | 4.8 |
| implied vol | 0.0 |
| beta | 9.5 |
| debt equity | 4.4 |
- ▸High IV: 86%
- ▸Concentration risks: 2 MED (10-K Item 1A)
Catalyst
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 6.0 |
- ▸Perfect beat streak: 4Q
- ▸Earnings today
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (5)
- MOMENTUM:7.4>=5.5
- INSIDER:OK
- NEWS_BOOST:EARNINGS:0.60
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:-1.0=NEGATIVE
- EARNINGS_PROXIMITY:0d<=7d
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-1.01
Upside
-15.2%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 59, MACD bullish
EdgeInst Constrain — Small cap ($1.7B) below institutional reach
SuitabilityAggressive — MCap $1.7B<$5B
Investment implication
The F-path SELL output reflects an overall score of 5.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Value at 7.5) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-1.0=NEGATIVE, EARNINGS_PROXIMITY:0d<=7d) reinforce the read. Current asymmetry R:R is -1.01 — supplementary context, not the trigger for this path.
The strongest dimensions are Value at 7.5, Momentum at 7.4, and Catalyst at 7.2; the weakest are Technical at 3.0, Peer rank at 3.4, and Risk (lower is worse) at 4.0. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of -1.01 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Earnings Beat Streak
Trip ifEPS surprise falls below 0% in the November 4 report, ending the 4-quarter beat streak.
- P2Cheap Valuation Strong Cash
Trip ifForward P/E rises above 15x from current 9.6x.
- P3Analyst Target Exceeded
Trip ifPrice rises more than 20% above the analyst target without target revisions.
- P4Declining Revenue Small Cap
Trip ifRevenue declines more than 5% year over year.
- P5Event Risk Short Interest
Trip ifShort interest exceeds 20% of float from current 12%.